Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3SYOK)

• Drug Name: CTP-543 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alopecia	ED70	Phase 2	[1]
Asthma	CA23	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 72704611
  TTD Drug ID: DM3SYOK

Molecule-Related Drug Atlas

Drug(s) Targeting Janus kinase 2 (JAK-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Momelotinib	DMF98Q0	Myelofibrosis	2A20.2	Approved	[3]
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[4]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[5]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Approved	[6]
Fedratinib	DM4ZBK6	Myelofibrosis	2A20.2	Approved	[7]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[8]
XL019	DMJ6F5C	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[9]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[10]
LY2784544	DMZASMP	Breast cancer	2C60-2C65	Phase 2	[11]
Momelotinib	DMF98Q0	Myelofibrosis	2A20.2	Approved	[3]
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[4]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[5]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Approved	[6]
Fedratinib	DM4ZBK6	Myelofibrosis	2A20.2	Approved	[7]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[8]
XL019	DMJ6F5C	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[9]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[10]
LY2784544	DMZASMP	Breast cancer	2C60-2C65	Phase 2	[11]

Drug(s) Targeting Janus kinase 1 (JAK-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[4]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[5]
Upadacitinib	DM32B5U	Rheumatoid arthritis	FA20	Approved	[12]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[13]
SHR0302	DMUL8ZT	Ulcerative colitis	DD71	Phase 3	[14]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[15]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[13]
PF-06700841	DMMGSFV	Asthma	CA23	Phase 2	[15]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[16]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[17]
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[4]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[5]
Upadacitinib	DM32B5U	Rheumatoid arthritis	FA20	Approved	[12]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[13]
SHR0302	DMUL8ZT	Ulcerative colitis	DD71	Phase 3	[14]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[15]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[13]
PF-06700841	DMMGSFV	Asthma	CA23	Phase 2	[15]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[16]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 1 (JAK-1)	TT6DM01	JAK1_HUMAN	Inhibitor	[2]
Janus kinase 2 (JAK-2)	TTRMX3V	JAK2_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03898479) Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4.
• [4] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [5] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [6] National Cancer Institute Drug Dictionary (drug id 609888).
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [8] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [9] Company report (Portola Pharmaceuticals)
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
• [11] Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013 Apr 12;3:e109.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
• [14] Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Clinical pipeline report, company report or official report of Aclaris Therapeutics.
• [17] ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.